EP Patent

EP4188384A1 — Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist

Assigned to Seagen Inc · Expires 2023-06-07 · 3y expired

What this patent protects

The present disclosure relates to a method of treating a HER2 positive cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a combination therapy comprising tucatinib, trastuzumab, a taxane, and a VEGFR-2 a…

USPTO Abstract

The present disclosure relates to a method of treating a HER2 positive cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a combination therapy comprising tucatinib, trastuzumab, a taxane, and a VEGFR-2 antagonist.

Drugs covered by this patent

Patent Metadata

Patent number
EP4188384A1
Jurisdiction
EP
Classification
—
Expires
2023-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Seagen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.